Sagimet Biosciences Return on Equity (ROE) Growth & History (SGMT)
Sagimet Biosciences's return on equity was −38.20% for fiscal 2025.
View full Sagimet Biosciences company overviewSagimet Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −38.20% | −1.29 pp |
| 2024 | 2024-12-31 | −36.92% | — |
Sagimet Biosciences quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.78% | −0.06 pp |
| Q1 2026 | 2026-03-31 | −9.96% | +2.37 pp |
| Q4 2025 | 2025-12-31 | −8.30% | +1.63 pp |
| Q3 2025 | 2025-09-30 | −10.35% | −2.09 pp |
| Q2 2025 | 2025-06-30 | −7.72% | −3.37 pp |
| Q1 2025 | 2025-03-31 | −12.33% | −7.61 pp |
| Q4 2024 | 2024-12-31 | −9.92% | −1.30 pp |
| Q3 2024 | 2024-09-30 | −8.26% | — |
| Q2 2024 | 2024-06-30 | −4.35% | — |
| Q1 2024 | 2024-03-31 | −4.72% | — |
| Q4 2023 | 2023-12-31 | −8.63% | — |
Sagimet Biosciences return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Sagimet Biosciences's return on equity decreased from −36.92% to −38.20%, a change of −1.29 percentage points. The latest reported quarter, Q2 2026, shows −7.78%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sagimet Biosciences source filings ↗